Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.72 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.72 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.72 |
| ▸ | NOS1 | P29475 | 1/20 | 0.57 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.57 |
| ▸ | HMOX1 | P09601 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1848631 | 0.84 | CYP11B1 (1.00) | CYP11B1ADRA2CCYP11B2CYP19A1 | |
| SCHEMBL6987181 | 0.81 | CYP11B1 (0.72) | CYP11B1CYP11B2HMOX1CYP19A1 | |
| SCHEMBL6991263 | 0.81 | CYP11B1 (0.72) | CYP11B1CYP11B2HMOX1CYP19A1 | |
| SCHEMBL27508985 | 0.81 | CYP11B1 (0.51) | CYP11B1ADRA2CCYP11B2HMOX1CYP19A1 | |
| SCHEMBL6988826 | 0.81 | CYP11B1 (0.72) | CYP11B1CYP11B2HMOX1ALDH1A1CYP19A1 | |
| SCHEMBL6986190 | 0.80 | HMOX1 (0.79) | CYP11B1CYP11B2NOS1HMOX1CYP19A1 | |
| SCHEMBL409741 | 0.80 | HMOX1 (0.72) | CYP11B1CYP11B2HMOX1CYP19A1 | |
| SCHEMBL17572351 | 0.79 | CYP11B1 (0.60) | CYP11B1ADRA2CCYP11B2NOS1HMOX2 | |
| Bromide SCHEMBL29223796 | 0.78 | HMOX1 (0.70) | CYP11B1CYP11B2HMOX1CYP19A1 | |
| Hydrochloric Acid SCHEMBL7527357 | 0.78 | HMOX1 (0.70) | CYP11B1CYP11B2HMOX1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101193886-B | New tricyclic angiotensin II agonists | VICORE PHARMA AB | 2014-08-27 | — | — | CN | disclosed |
| EP-1869023-B1 | NEW TRICYCLIC ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2012-01-11 | — | — | EP | disclosed |
| US-8080571-B2 | Tricyclic angiotensin II agonists | VICORE PHARMA AB (SE) | 2011-12-20 | — | — | US | disclosed |
| US-20090042931-A1 | Tricyclic Angiotensin II Agonists | VICORE PHARMA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| CN-101193886-A | New tricyclic angiotensin II agonists | VICORE PHARMA AB (SE) | 2008-06-04 | — | — | CN | disclosed |
| EP-1869023-A1 | NEW TRICYCLIC ANGIOTENSIN II AGONISTS | Vicore Pharma AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006109048-A1 | NEW TRICYCLIC ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042931-A1 | Tricyclic Angiotensin II Agonists | AGTR2, AGTR1, NPY4R | CYP11B1 920/4885ADRA2C 178/4885CYP11B2 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.